Clin2
NCT07567872Possibly a fitRecruiting

Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients

COPD

Part of Lungs & breathing clinical trials.

This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
48 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are willing and able to give informed consent and follow all study procedures
  • Your body weight is at least 45 kg and your BMI (weight-to-height ratio) is between 18–33
  • Your heart rhythm (ECG) is normal or has only minor, non-concerning abnormalities
  • You agree to use contraception (birth control) for 1–3 months after the last dose
  • You can use the study inhaler device correctly as instructed

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07640451Recruiting· Phase 2
HRS-9821 inhalation treatment for moderate to severe COPD

This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.

Shanghai, Shanghai Municipality
NCT07285122Recruiting· Phase 1
Inhaled study drug for healthy smokers and people with COPD

This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.

Nedlands, Western Australia
NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality
NCT07822334Not yet recruiting· Phase 1/Phase 2
Study of an investigational drug for chronic obstructive pulmonary disease

This study tests an experimental medication for chronic obstructive pulmonary disease (COPD) in two parts: first in healthy volunteers, then in people with COPD. It aims to see if the drug is safe and how well it works.

NCT07140328Recruiting· Phase 2
Testing a new inhaler for COPD symptoms

This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.

Nanchang, Jiangsu
NCT07658339Not yet recruiting· Phase 3
Inhaled treatment for chronic obstructive pulmonary disease

This trial tests an inhaled medication for COPD. It aims to see if the treatment is safe and helps improve breathing and symptoms.

Beijing

Hear when a new COPD trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.